PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: Johnson & Johnson
Johnson & Johnson Slammed Over Manufacturing Practices, Phantom Recall
In 1982, Johnson & Johnson garnered an enduring amount of goodwill when, seemingly without any thought of lost profit, it immediately yanked Tylenol from the shelves nationwide after learning someone was slipping cyanide into bottles in Chicago. The company’s sure and swift PR response became the model for crisis management for the corporate world.
But in [...]
Posted in Corporate Responsibility Also tagged Congressional hearing, FDA, House Oversight Committee, J&J, Manufacturing, McNeil, Motrin, phantom recall, recall, Tylenol 3 Comments
A Critical Path to New TB Treatments
Image via Wikipedia
FDA Commissioner Margaret Hamburg announced, on Thursday, a new joint initiative between industry, FDA, and non-profit organizations designed to fast-track modern combination treatments for tuberculosis. Where once it took more than two decades to create new therapies for TB, this collaboration is expected to produce working treatments in less than six years, providing [...]
Posted in R&D Also tagged Bill & Melinda Gates Foundation, Clinical trial, Developing country, Health, Mel Spigelman, TB Alliance, Tuberculosis 2 Comments
Pharma and Haiti: Can Altruism Backfire?
Guest blog by Pharm Exec Europe’s Jacky Law.
Pharma companies are responding swiftly to the recent earthquake in Haiti with millions of dollars in cash and drugs. GlaxoSmithKline boasted, for example, that its initial $1.2 million offering of medicines — mainly oral and topical antibiotics — was on the first airlift to the Caribbean island and [...]
Posted in Corporate Responsibility, Global, Guest Blog, News Also tagged Big Pharma, corporate social responsibility, donations, Haiti, Pharma Leave a comment
Feds Chase Down Faulty Skincare Promos
FDA’s Division of Drug Marketing Communications, this week, posted a slew of warning and untitled letters to pharma firms for misleading skincare advertisements. Johnson & Johnson, Galderma, and Allergan each received a letter documenting complaints ranging from false advertising to unsubstantial efficacy claims.
J&J received a violation letter in response to a journal ad for its [...]
Posted in FDA, Marketing Also tagged Advertising, Allergan, Clinical trial, U.S. Food and Drug Administration 2 Comments
European Commission Investigates J&J, Novartis